Brokers Set Expectations for ACRV Q1 Earnings

Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Free Report) - Stock analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Acrivon Therapeutics in a research note issued on Wednesday, March 26th. HC Wainwright analyst E. Bodnar anticipates that the company will post earnings per share of ($0.63) for the quarter. HC Wainwright currently has a "Buy" rating and a $19.00 price target on the stock. The consensus estimate for Acrivon Therapeutics' current full-year earnings is ($2.49) per share. HC Wainwright also issued estimates for Acrivon Therapeutics' Q2 2025 earnings at ($0.53) EPS, Q3 2025 earnings at ($0.54) EPS, Q4 2025 earnings at ($0.56) EPS, FY2025 earnings at ($2.30) EPS, FY2026 earnings at ($2.77) EPS, FY2027 earnings at ($2.31) EPS and FY2028 earnings at ($1.96) EPS.

Several other analysts have also recently commented on ACRV. Cantor Fitzgerald restated an "overweight" rating on shares of Acrivon Therapeutics in a research note on Wednesday, March 26th. KeyCorp initiated coverage on Acrivon Therapeutics in a report on Friday, January 31st. They issued an "overweight" rating on the stock. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $23.17.

Acrivon Therapeutics Stock Down 14.5 %

NASDAQ:ACRV traded down $0.30 during midday trading on Friday, reaching $1.74. The stock had a trading volume of 282,732 shares, compared to its average volume of 100,715. The stock has a market cap of $54.02 million, a P/E ratio of -0.64 and a beta of 0.85. The firm has a fifty day simple moving average of $5.27 and a two-hundred day simple moving average of $6.45. Acrivon Therapeutics has a 12-month low of $1.77 and a 12-month high of $11.90.

Acrivon Therapeutics (NASDAQ:ACRV - Get Free Report) last announced its earnings results on Thursday, March 27th. The company reported ($0.60) earnings per share for the quarter, beating the consensus estimate of ($0.69) by $0.09.

Institutional Trading of Acrivon Therapeutics

A number of institutional investors have recently added to or reduced their stakes in ACRV. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Acrivon Therapeutics during the 4th quarter valued at approximately $40,000. Wealthedge Investment Advisors LLC purchased a new stake in Acrivon Therapeutics during the fourth quarter worth $65,000. Corton Capital Inc. acquired a new stake in Acrivon Therapeutics in the fourth quarter valued at $73,000. American Century Companies Inc. increased its position in shares of Acrivon Therapeutics by 14.2% in the fourth quarter. American Century Companies Inc. now owns 17,588 shares of the company's stock valued at $106,000 after buying an additional 2,186 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in shares of Acrivon Therapeutics by 20.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 37,063 shares of the company's stock worth $223,000 after buying an additional 6,239 shares during the last quarter. Hedge funds and other institutional investors own 71.62% of the company's stock.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.